Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $130
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a Buy rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $97 to $130.
May 03, 2024 | 9:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia maintains a Buy rating on Blueprint Medicines and raises the price target from $97 to $130.
The increase in price target by Needham reflects a positive outlook on Blueprint Medicines, suggesting confidence in the company's future performance. This analyst action can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100